Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

A robust documentation strategy is the foundation for successful Advanced Therapy Medicinal Product (ATMP) manufacturing and subsequent Investigational Medicinal Product Dossier (IMPD) submissions to the MHRA. This involves creating a comprehensive data package that details process development, vector characterization, and quality control from the earliest stages. Proactive documentation minimizes regulatory friction, accelerates timelines, and provides a clear path for tech transfer into GxP-compliant production environments.

The Regulatory Framework: Aligning with MHRA for ATMPs

For innovators targeting MHRA submission, navigating the agency’s requirements for ATMPs demands a documentation strategy that is both comprehensive and scientifically justified. The agency expects a clear narrative connecting the vector’s design to its intended clinical function and safety profile. A well-structured data repository that anticipates regulatory scrutiny is a requirement for a successful submission.

A frequent challenge is the retroactive assembly of data from disparate research-grade experiments. This approach often fails to meet the rigorous standards for an IMPD submission. A proactive strategy ensures that all process steps, from plasmid sourcing to final fill, are documented under principles that will later support GxP compliance.

Core Components of a GxP-Ready Documentation Package

A successful tech transfer hinges on the quality and completeness of the accompanying documentation. The objective is to enable a receiving manufacturing organization to replicate the process with precision and confidence.

Key elements include:

• Vector & Plasmid Lineage: Full traceability of all starting materials, including host cell banks and plasmid constructs.

• Process Flow Diagrams: Detailed schematics of the entire manufacturing process, outlining unit operations and in-process controls.

• Batch Production Records (BPRs): Master templates that define every manufacturing step, parameter, and material addition.

• Standard Operating Procedures (SOPs): Formal instructions for all routine operations, from equipment use to environmental monitoring.

• Analytical Method Summaries: Descriptions of all assays used for product characterization, release testing, and stability studies, including their qualification status.

From Process Definition to IMPD Submission

The scientific rationale underpinning vector design is a focal point for regulators. For instance, the selection of a specific AAV serotype must be justified. Data on the global prevalence of neutralizing antibodies, particularly for common serotypes like AAV1 and AAV2, informs the product’s risk profile and must be addressed in the documentation (PMID: 19133809).

Similarly, choices regarding genetic elements, such as the use of a liver-restricted promoter to achieve sustained expression and potentially induce immune tolerance, must be supported by robust preclinical data (PMID: 14759807). This information becomes a core part of the CMC section of an IMPD, demonstrating a deep understanding of the product’s biological activity and safety mechanisms. Our >100,000 sq ft facility provides the GxP-compliant environment to generate this data, supporting an 18-24 month timeline to IND.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is an essential collaborator in our AAV-vector based gene therapy candidate development, and we hope to continue the partnership for years to come.”
— Biotech Partner

Proactive Tech Transfer for UK-Based Sponsors

For UK-based sponsors, a well-managed tech transfer is a significant value inflection point. Franklin Biolabs, which launched in 2024, inherits the operational expertise that contributed to a 100% successful IND rate since 2019. We provide sponsors with a documentation package designed for efficient transfer into GMP manufacturing suites, whether internal or at a third-party facility. This preparation de-risks the path to clinical trials by ensuring manufacturing consistency and regulatory alignment from the outset, enabling a seamless tech transfer that accelerates GMP readiness.